

## Index

- A1C. *see also* glycemic targets  
 CGM, S34  
 children and adolescents, S35, S71  
 glycemic target determination, S37  
 goals, S35  
 limitations, S34–S35  
 macrovascular complications, S36  
 mean glucose levels, S35  
 microvascular complications, S35–S36  
 race/ethnicity differences, S9, S35  
 recommendations, S34, S35, S37  
 SMBG, S33–S34  
 testing, S8–S10, S12, S34–S35
- acarbose, S44  
 ACCORD trial, S19, S36, S38, S50, S53  
 A1C Derived Average Glucose (ADAG) trial, S35, S37  
 ACE inhibitors, S49–S51, S55, S58–S60, S72, S78  
 acute coronary syndrome, S54, S55  
 adolescents. *see* children and adolescents  
 ADVANCE-BP trial, S50, S51  
 ADVANCE trial, S36, S38  
 advocacy, S5, S86–S87  
 African Americans, S9, S11, S12, S24, S35  
 age. *see* older adults  
 AIM-HIGH trial, S53  
 albiglutide, S45  
 albuminuria, S25, S58–S60, S73  
 alcohol, S23, S51  
 alogliptin, S44  
 amlodipine, S51  
 amputations, S63–S64  
 amylin mimetics, S45  
 anemia, S9  
 angiotensin receptor blockers (ARBs), S49–S51, S55, S58–S60, S72, S78  
 ankle-brachial index (ABI), S63, S64  
 antihypertensive medications, S51, S59, S78  
 antiplatelet agents, S54–S55, S61  
 Antithrombotic Trialists' (ATT) Collaboration, S54  
 Asian Americans, S9–S12  
 aspart, S43, S45  
 aspirin resistance, S55  
 aspirin therapy, S54–S55, S61  
 assisted living. *see* hospital care  
 autoimmune disease, S10–S11  
 Automation to Simulate Pancreatic Insulin Response (ASPIRE) trial, S34  
 autonomic neuropathy, S25, S62–S63
- bariatric surgery, S46–S47  
 benazepril, S51  
 biguanides, S31, S32, S42–S44  
 bile acid sequestrants, S42, S44, S53  
 $\beta$ -blockers, S51, S55  
 blood pressure control. *see* hypertension  
 body mass index (BMI), S12  
 bromocriptine, S42, S45
- calcium channel blockers, S51, S59  
 canagliflozin, S45  
 cancer, S18  
 carbohydrates, S21–S23
- cardiovascular disease  
 A1C relationship to, S36  
 autonomic neuropathy, S25, S62–S63  
 children and adolescents, S72  
 dietary fat management, S23–S24  
 patient-centeredness, S5  
 pharmacological therapy, S51–S55, S59  
 postprandial plasma glucose testing, S37  
 revisions summary, S4  
 risk calculator, S52  
 risk factors, S10, S12, S25, S32  
 risk management, S49–S55  
 screening, S31, S55  
 testing frequency, S9
- Care of Young Children With Diabetes in the Child Care Setting*, S86  
 celiac disease, S71  
 Charcot foot, S64  
 children and adolescents  
 A1C goals, S35, S71  
 autoimmune conditions, S71  
 cardiovascular disease, S72  
 celiac disease, S71  
 cognitive impairment, S70  
 DSME/DSMS, S73  
 dyslipidemia, S72  
 family stresses, S74  
 glycemic control, S70–S71  
 hypertension, S71–S72  
 hypoglycemia, S70  
 nephropathy, S72–S73  
 neuropathy, S73  
 pediatric to adult care transition, S73–S74  
 plasma blood glucose goals, S71  
 psychosocial issues, S74  
 resources, S86  
 retinopathy, S73  
 revisions summary, S4  
 school, child care, S73  
 smoking, S72  
 statins, S72  
 thyroid disease, S71  
 type 1 diabetes, S10–S11, S70–S74  
 type 2 diabetes, S12–S13, S74
- chlorthalidone, S51  
 cholesterol. *see also* dyslipidemia  
 children and adolescents, S72  
 control, S51  
 monitoring, S53  
 screening, S10, S52  
 treatment, S52, S55
- Chronic Care Model (CCM), S5, S6  
 chronic kidney disease, S23, S25, S58–S60  
 classification, diagnosis  
 overview, S8  
 prediabetes, S9–S10, S12–S13  
 revisions summary, S4  
 testing, S8–S10  
 testing frequency, S9
- claudication, S63  
 clinical management  
 advocacy, S5, S86–S87  
 behavior change support, S6  
 behavior optimization, S6  
 care delivery systems, S6
- changes, initiatives, S6  
 demographic changes, S5  
 improvement strategies, S5  
 patient-centeredness, S5  
 regime reevaluation, S6–S7  
 resources, S6
- clonidine, S78  
 clopidogrel, S54, S55  
 cognitive impairment, S19, S38, S70  
 colesevelam, S42, S44  
 comorbidities, S17–S19, S26  
 congestive heart failure, S51, S55  
 consensus reports, S1  
 continuous glucose monitoring (CGM), S4, S33, S34  
 continuous subcutaneous insulin infusion (CSII), S83  
 contraception, S79  
 coronary heart disease, S55  
 cystic fibrosis–related diabetes, S15
- dapagliflozin, S45  
 Da Qing study, S31  
 DAWN2 study, S26  
 day care, S73, S86–S87  
 degludec, S45  
 depression, S18, S26, S67, S74  
 detemir, S45  
*Diabetes and Driving*, S86  
*Diabetes and Employment*, S86  
*Diabetes Care in the School and Day Care Setting*, S86–S87  
 Diabetes Control and Complications Trial (DCCT), S35, S36, S38, S41, S70  
*Diabetes Management in Correctional Institutions*, S87  
 Diabetes Prevention Program (DPP), S31, S32  
 Diabetes Prevention Program Outcomes Study (DPPOS), S31, S32  
 diabetes-related distress, S26  
 diabetes self-management education (DSME)  
 benefits, S6, S20–S21  
 carbohydrate management, S21–S23  
 children and adolescents, S73  
 dietary fat management, S23–S24  
 eating patterns, S21–S23  
 herbal supplements, S23  
 hospital care, S84  
 medical nutrition therapy, S21–S23, S52, S72, S83  
 micronutrients, S23  
 national standards, S21  
 overview, S17, S20–S21  
 prediabetes, S32  
 protein management, S22, S23, S59  
 recommendations, S20, S31  
 reimbursement, S21  
 sodium, S23, S24, S51  
 weight loss, S21, S55
- diabetes self-management support (DSMS). *see* diabetes self-management education (DSME)  
 Diabetic Retinopathy Study (DRS), S61  
 diastolic blood pressure goals, S4

- diet, nutrition, S21–S23  
diltiazem, S78  
dipeptidyl peptidase 4 (DPP-4) inhibitors, S42–S44, S46, S68  
disordered eating, S74  
diuretics, S49–S51, S58, S59, S78  
dopamine-2 agonists, S45  
driving, S86  
dulaglutide, S45  
dyslipidemia. *see also* cholesterol; triglycerides  
    children and adolescents, S72  
    control, S51  
    lifestyle modification, S52, S55  
    monitoring recommendations, S4, S53  
    recommendations, S51–S52  
    screening, S51  
    treatment, S52–S55
- Early Treatment Diabetic Retinopathy Study (ETDRS), S61  
eating abnormalities, S74  
eating patterns, S21–S23  
e-cigarettes, S4, S25  
empagliflozin, S45  
employment, S86  
end-stage renal disease (ESRD), S59  
Epidemiology of Diabetes Interventions and Complications (EDIC) study, S35–S36, S38  
erectile dysfunction, S63  
exenatide/exenatide ER, S45, S82  
exercise  
    albuminuria, S25  
    autonomic neuropathy, S25, S62–S63  
    benefits, S24  
    children, S24  
    frequency, type, S24  
    glycemic control, S24  
    hyperglycemia, S25  
    hypoglycemia, S25  
    kidney disease, S23, S25, S58–S60, S72–S73  
    peripheral neuropathy, S25, S62–S63  
    prediabetes, S24  
    pre-exercise evaluation, S24–S25  
    recommendations, S24  
    retinopathy, S25, S60–S62, S73  
ezetimibe, S53
- fasting plasma glucose testing, S9  
fatty liver disease, S18  
fenofibrate, S53  
fibrates, S53  
Finnish Diabetes Prevention Study (DPS), S31  
foot care, S4, S63–S64  
foot infections, S64  
foundations of care revisions summary, S4  
fractures, S18–S19  
FRAX score, S18  
fundus photographs, S61
- gastrointestinal neuropathies, S62  
gastroparesis, S63  
genitourinary tract disturbances, S62–S63  
gestational diabetes mellitus (GDM). *see also* pregnancy  
    classification, S8  
    diagnosis, S13–S14  
    glycemic targets, S77, S78  
    management, S78  
    one-step strategy, S13, S14  
    overview, S13, S77
- postpartum care, S79  
recommendations, S13  
screening, S10  
two-step strategy, S13–S14
- glargine, S45  
gliclazide, S44  
gliimepiride, S44  
glipizide, S44  
glucagon, S38  
glucagon-like peptide 1 (GLP-1) agonists, S42, S43, S45, S46, S68, S82  
 $\alpha$ -glucosidase inhibitors, S42, S44  
glulisine, S43, S45  
glyburide/glibenclamide, S44  
glycemic targets. *see also* A1C  
    A1C/microvascular complications  
        relationships, S35–S36  
        determination, S37  
    glycemic control assessment, S33–S35  
    hospital care, S80–S82  
    intercurrent illness, S39  
    mean glucose levels, S35  
    mortality findings, S36  
    older adults, S68  
    pregnancy, S77, S78  
    recommendations, S33, S36–S37  
    revisions summary, S4  
glycemic treatment approaches  
    bariatric surgery, S46–S47  
    pharmacological therapy, S41–S46  
    revisions summary, S4  
gram-positive cocci, S64
- hearing impairment, S19  
hemoglobinopathies, S9  
hepatitis B vaccination, S26  
herbal supplements, S23  
hospital care  
    bedside blood glucose monitoring, S83  
    critically ill patients, S80, S81  
    discharge planning, S80, S83  
    DSME, S84  
    glucose abnormalities definitions, S81  
    glycemic targets, S80–S82  
    hyperglycemia, S80–S81  
    hypoglycemia, S80–S82  
    insulin therapy, S80–S82  
    management team, S82  
    medical nutrition therapy, S83  
    medication reconciliation, S83  
    non critically ill patients, S80–S82  
    recommendations, S80  
    self-management, S82–S83  
    sliding scale insulin (SSI), S80, S82  
    structured discharge communication, S83  
    type 1 diabetes, S82
- hydrochlorothiazide, S51  
hyperglycemia  
    cognitive impairment, S19  
    exercise, S25  
    glycemic target determination, S37  
    hospital care, S80–S81  
    older adults, S67, S68  
    plasma glucose testing, S9  
    postprandial, S37  
    risk factors, S11
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S13  
hyperglycemic crisis, S9  
hypertension  
    children and adolescents, S71–S72  
    diagnosis, S49, S50
- diastolic blood pressure, S50–S51  
goals, S49, S50  
lifestyle modification, S49, S51  
older adults, S67  
overview, S49–S50  
pharmacological therapy, S49–S51  
recommendations, S49  
screening, S10, S49, S50  
sodium guidelines, S24, S51  
systolic blood pressure, S50, S59  
treatment, S49, S50
- Hypertension Optimal Treatment (HOT) trial, S50  
hypertriglyceridemia, S53  
hypoglycemia  
    A1C goals, S35, S37  
    CGM, S34  
    children and adolescents, S70  
    exercise, S25  
    hospital care, S80–S82  
    nocturnal, S34  
    older adults, S68  
    overview, S38  
    pregnancy, S78  
    prevention, S38, S82  
    recommendations, S38  
    treatment, S38  
hypoglycemia unawareness  
    CGM, S33, S34  
    children and adolescents, S70  
    effects, characterization, S38  
    recommendations, S38
- immune-mediated diabetes, S10–S11  
immunization recommendations, S4, S26–S27  
impaired fasting glucose (IFG), S10, S31  
impaired glucose tolerance (IGT), S10, S31  
incretin-based therapies, S42  
indapamide, S50, S51  
infections, S64  
influenza vaccine, S26–S27  
insulin  
    basal–bolus, S43, S45, S46, S70, S71, S82  
    combination therapy, S42  
    glycemic targets, S38  
    hospital care, S80–S82  
    hypoglycemia treatment, S38  
    intensive insulin regimens, S34  
    MDI, S41  
    older adults, S68  
    pregnancy, S78  
    recommendations, S33  
    sliding scale insulin (SSI), S80, S82  
    type 1 diabetes, S41  
    type 2 diabetes, S42–S46  
insulin dependent diabetes, S10–S11  
insulin pump therapy, S33, S41, S43, S83  
insulin resistance, S10, S78  
insulin secretagogues, S38, S68  
International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S13
- jail, S87  
juvenile-onset diabetes, S10–S11
- kidney disease, S23, S25, S58–S60, S72–S73  
Kumamoto Study, S36
- labetalol, S78  
lactation, S79

- laser photocoagulation therapy, S61–S62
- lifestyle modifications
- dyslipidemia, S52, S55
  - hypertension, S49, S51
  - type 2 diabetes, S31, S42
- linagliptin, S44
- liraglutide, S45
- lispro, S43, S45
- lixisenatide, S45
- Look AHEAD trial, S18, S55
- loss of protective sensation (LOPS), S63, S64
- macrovascular complications, S35, S36, S51
- macular edema, S61
- management planning, S17–S19, S26
- maturity-onset diabetes of the young (MODY), S14
- medical evaluation, S17, S18, S24–S25
- medical nutrition therapy, S21–S23, S52, S72, S83
- Medicare/Medicaid, S21
- medications, S12. *see also* pharmacological therapy; *specific medications, conditions*
- meglitinides, S42, S44
- mental health specialist referrals, S26
- metformin, S31, S32, S42–S44, S55, S59, S68
- methyl dopa, S78
- microvascular complications
- A1C goals, S35
  - A1C relationship to, S35–S36
  - erectile dysfunction, S63
  - gastroparesis, S63
  - glycemic control, S63
  - kidney disease, S23, S25, S58–S60, S72–S73
  - neuropathy, S25, S62–S63, S73
  - orthostatic hypotension, S63
  - patient education, S64
  - pharmacological therapy, S51
  - retinopathy, S25, S60–S62, S73
  - revisions summary, S4
  - risk factors, S11
- migliol, S44
- monogenic diabetes syndromes, S14–S15
- myocardial infarction (MI), S36, S50, S54, S55, S59
- nateglinide, S44
- National Diabetes Education Program (NDEP), S6, S74
- National Diabetes Prevention Program, S31
- National Institutes of Health (NIH), S13–S14
- neonatal diabetes, S14
- nephropathy, S23, S25, S58–S60, S72–S73
- neuropathy, S25, S62–S63, S73
- niacin, S53
- NICE-SUGAR trial, S81
- nonproliferative diabetic retinopathy (NPDR), S61
- nursing home. *see* hospital care
- obstructive sleep apnea, S18
- older adults
- A1C levels, S9
  - depression screening, S67
  - diabetes complications screening, S67
  - glycemic targets, S68
  - hyperglycemia, S67, S68
  - hypertension, S67
- hypoglycemia, S68
- pharmacological therapy, S68–S69
- recommendations, S67
- sodium guidelines, S24
- statin therapy, S52, S53
- treatment goals, S67–S68
- type 2 diabetes screening, S12
- orthostatic hypotension, S63
- overweight, obesity, S9, S10, S21, S55, S78–S79
- Patient-Centered Medical Home, S6
- perindopril, S50, S51
- periodontal disease, S19
- peripheral arterial disease, S63, S64
- peripheral neuropathy, S25, S62–S63
- pharmacological therapy
- cardiovascular disease, S51–S55, S59
  - hypertension, S49–S51
  - microvascular complications, S51
  - older adults, S68–S69
  - prediabetes, S32
  - type 2 diabetes, S31–S32, S42–S46
- pioglitazone, S44, S46
- pneumococcal polysaccharide vaccine 23 (PPSV23), S26, S27
- polycystic ovary syndrome, S10
- position statements, S1
- pramlintide, S41–S42, S45
- prasugrel, S55
- prazosin, S78
- prediabetes
- classification, diagnosis, S9–S10, S12–S13
  - DSME/DSMS, S32
  - exercise, S24
  - pharmacological therapy, S32
- pre-exercise medical evaluation, S24–S25
- pregnancy
- A1C testing, S9, S78
  - antihypertensive medications, S51, S78
  - contraception, S79
  - GDM (*see* gestational diabetes mellitus [GDM])
  - glycemic targets, S77, S78
  - hypertension, S50
  - hypoglycemia, S78
  - insulin, S78
  - insulin resistance, S78
  - lactation, S79
  - medications contraindicated, S77, S78
  - metabolic physiology, S78
  - overweight, obesity, S78–S79
  - postpartum care, S79
  - preconception counseling, S77
  - recommendations, S77
  - retinopathy, S25, S60–S62, S73
  - revisions summary, S4
  - screening, S10
  - statins, S72
- prison, S87
- Professional Practice Committee, S3, S88–S89
- proliferative diabetic retinopathy, S61
- protein, S22, S23, S59
- psychosocial screening, care, S25–S26
- P2Y12 receptor antagonist, S55
- race/ethnicity, S9, S12, S35. *see also* African Americans; Asian Americans
- RAS inhibitors, S51, S59
- repaglinide, S44
- retinal photography, S61
- retinopathy, S25, S60–S62, S73
- revisions summary, S4
- Reye syndrome, S54
- risk management, S4, S6, S9, S11
- rosiglitazone, S44
- SAVOR-TIMI 53 trial, S68–S69
- saxagliptin, S44, S68–S69
- school, S73, S86–S87
- scientific evidence grading, S1–S2
- scientific statements, S1
- self-monitoring of blood glucose (SMBG)
- basal insulin/oral agents, S34
  - intensive insulin regimens, S34
  - optimization, S33–S34
  - overview, S33
  - recommendations, S33
- sickle cell trait, S9
- sitagliptin, S44, S82
- skilled nursing facilities. *see* hospital care
- sliding scale insulin (SSI), S80, S82
- smoking, S4, S25, S63, S72
- sodium, S23, S24, S51
- sodium–glucose cotransporter 2 (SGLT2) inhibitors, S42, S43, S45, S46
- Standards of Care recommendations, S1
- Staphylococci, S64
- statins, S4, S52–S55, S72
- stroke, S36, S54, S59
- sulfonylureas
- A1C/CVD relationships, S36
  - combination therapy, S42, S43
  - older adults, S68
  - type 2 diabetes, S43, S44, S46
- testosterone levels, S19
- thiazolidinediones, S43, S44, S46
- thyroid disease, S71
- ticagrelor, S55
- triglycerides, S10, S52, S53. *see also* dyslipidemia
- 2-hour plasma glucose testing, S9
- type 1 diabetes
- A1C/mean glucose relationship, S35
  - autoimmune conditions, S71
  - carbohydrate management, S21
  - CGM, S33, S34
  - children and adolescents, S10–S11, S70–S74
  - classification, S8
  - diagnosis, S10–S11
  - glycemic control, S70–S71
  - hospital care, S82
  - hypoglycemia, S38
  - insulin, S41
  - pharmacological therapy, S41–S42
  - pregnancy, S78–S79
  - progression estimates, S11
  - retinopathy, S25, S60–S62, S73
  - SMBG, S34
  - statin therapy, S53
  - testing, S11
- type 2 diabetes
- A1C goals, S35
  - A1C/macrovascular complications relationships, S36

children and adolescents, S12–S13, S74  
classification, S8  
combination therapy, S42, S43  
community screening, S12  
comorbidities, S74  
diagnosis, S11–S13  
diagnostic tests, S12  
hypoglycemia, S38  
ketoacidosis, S11  
lifestyle modifications, S31, S42

overview, S11  
pharmacological therapy, S31–S32, S42–S46  
pregnancy, S78–S79  
prevention, delay of, S31–S32  
recommendations, S11, S31  
retinopathy, S25, S60–S62, S73  
risk factors, S11–S12  
screening, S12, S31  
testing interval, S12

UK Prospective Diabetes Study (UKPDS), S36, S59  
ulcers, S63–S64  
vascular endothelial growth factor (VEGF), S61, S62  
vascular pathology measures, S37  
Veterans Affairs Diabetes Trial (VADT), S36  
vildagliptin, S44  
weight loss, S21, S55